Archford Capital Strategies’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.52M Sell
27,354
-6,991
-20% -$818K 0.36% 69
2026
Q1
$4.13M Buy
34,345
+22,076
+180% +$2.55M 0.47% 54
2025
Q4
$1.29M Sell
12,269
-92
-0.7% -$8.64K 0.15% 135
2025
Q3
$1.04M Sell
12,361
-73
-0.6% -$6.01K 0.12% 159
2025
Q2
$984K Buy
12,434
+43
+0.3% +$3.42K 0.13% 151
2025
Q1
$1.11M Buy
12,391
+42
+0.3% +$3.92K 0.16% 135
2024
Q4
$1.23M Sell
12,349
-243
-2% -$25.1K 0.19% 124
2024
Q3
$1.38M Buy
12,592
+421
+3% +$50K 0.21% 110
2024
Q2
$1.51M Sell
12,171
-182
-1% -$23.4K 0.24% 98
2024
Q1
$1.63M Buy
12,353
+104
+0.8% +$12.8K 0.27% 96
2023
Q4
$1.34M Buy
12,249
+738
+6% +$76.6K 0.24% 107
2023
Q3
$1.19M Buy
11,511
+2,234
+24% +$241K 0.24% 104
2023
Q2
$1.01M Buy
9,277
+2,091
+29% +$237K 0.19% 126
2023
Q1
$804K Buy
7,186
+1,048
+17% +$113K 0.17% 139
2022
Q4
$681K Buy
6,138
+159
+3% +$16.3K 0.16% 157
2022
Q3
$515K Buy
5,979
+201
+3% +$17.9K 0.13% 176
2022
Q2
$527K Sell
5,778
-391
-6% -$34.7K 0.13% 173
2022
Q1
$516K Buy
6,169
+1,419
+30% +$112K 0.12% 179
2021
Q4
$364K Buy
4,750
+1,269
+36% +$101K 0.08% 221
2021
Q3
$261K Sell
3,481
-517
-13% -$39.3K 0.06% 272
2021
Q2
$311K Sell
3,998
-2,567
-39% -$191K 0.08% 233
2021
Q1
$480K Buy
6,565
+255
+4% +$18.8K 0.13% 178
2020
Q4
$500K Sell
6,310
-112
-2% -$8.57K 0.12% 184
2020
Q3
$508K Sell
6,422
-363
-5% -$28.4K 0.14% 169
2020
Q2
$501K Sell
6,785
-283
-4% -$21.3K 0.15% 154
2020
Q1
$519K Sell
7,068
-1,846
-21% -$145K 0.2% 143
2019
Q4
$774K Sell
8,914
-1,751
-16% -$144K 0.27% 118
2019
Q3
$857K Buy
10,665
+2,044
+24% +$164K 0.32% 97
2019
Q2
$690K Sell
8,621
-130
-1% -$9.95K 0.25% 116
2019
Q1
$694K Sell
8,751
-656
-7% -$49.1K 0.26% 118
2018
Q4
$686K Buy
9,407
+518
+6% +$36.6K 0.28% 110
2018
Q3
$602K Buy
8,889
+392
+5% +$25K 0.22% 130
2018
Q2
$492K Buy
8,497
+5,875
+224% +$331K 0.17% 154
2018
Q1
$142K Buy
+2,622
New +$142K 0.06% 138
2017
Q4
Sell
-4,168
Closed -$255K 195
2017
Q3
$255K Buy
4,168
+1
+0% +$61 0.1% 177
2017
Q2
$255K Sell
4,167
-106
-2% -$6.45K 0.1% 169
2017
Q1
$259K Hold
4,273
0.1% 178
2016
Q4
$240K Hold
4,273
0.1% 162
2016
Q3
$254K Sell
4,273
-262
-6% -$15.3K 0.1% 165
2016
Q2
$249K Buy
4,535
+498
+12% +$26.5K 0.13% 138
2016
Q1
$204K Buy
4,037
+188
+5% +$9.21K 0.1% 164
2015
Q4
$194K Buy
3,849
+1,311
+52% +$66.1K 0.09% 169
2015
Q3
$120K Buy
2,538
+1
+0% +$53 0.09% 139
2015
Q2
$138K Hold
2,537
0.1% 132
2015
Q1
$139K Buy
2,537
+1,049
+70% +$59.4K 0.1% 133
2014
Q4
$81K Hold
1,488
0.06% 166
2014
Q3
$84K Buy
1,488
+1
+0.1% +$56 0.07% 164
2014
Q2
$82.1K Sell
1,487
-285
-16% -$15.5K 0.06% 167
2014
Q1
$96K Buy
+1,772
New +$91.8K 0.08% 161

Other funds holding MRK

Archford Capital Strategies's MRK Position: Q2 2026 in Review

Archford Capital Strategies reduced its Merck (MRK) stake by 20% in Q2 2026, selling an estimated $818K and leaving 27,354 shares worth $3.52M. The position accounts for 0.36% of the portfolio, ranked #69.

Archford Capital Strategies first reported a position in MRK in Q1 2014 and has held it in 49 quarters since. The position peaked at $4.13M in Q1 2026. 1,411 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Archford Capital Strategies held 27,354 shares of Merck worth $3.52M as of Q2 2026.
  • Archford Capital Strategies sold 6,991 Merck shares in Q2 2026, an estimated $818K.
  • Merck made up 0.36% of Archford Capital Strategies's portfolio in Q2 2026, its #69 holding.
  • Archford Capital Strategies first reported a position in Merck in Q1 2014 and has held it in 49 quarters since.
  • Archford Capital Strategies's Merck position peaked at $4.13M in Q1 2026.
  • 1,411 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Archford Capital Strategies's 13F filing for Q2 2026, filed 17 Jul 2026.